Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth doxorubicin with less toxicity

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Albright, C. F.
  • Graciani, N.
  • Han, W.
  • Yue, Eddy W
  • Stein, R.
  • Lai, Z.
  • Diamond, M.
  • Dowling, R.
  • Grimminger, L.
  • Zhang, S. Y.
  • Behrens, D.
  • Musselman, A.
  • Bruckner, R.
  • Zhang, M.
  • Jiang, X.
  • Hu, D.
  • Higley, A.
  • DiMeo, S.
  • Rafalski, M.
  • Mandlekar, S.
  • Car, B.
  • Yeleswaram, S.
  • Stern, A.
  • Copeland, R. A.
  • Combs, A.
  • Seitz, S. P.
  • Trainor, G. L.
  • Taub, R.
  • Huang, P.
  • Oliff, A.

publication date

  • May 2005

journal

  • Molecular Cancer Therapeutics  Journal

subject areas

  • Animals
  • Doxorubicin
  • Drug Screening Assays, Antitumor
  • Drug-Related Side Effects and Adverse Reactions
  • Fibrosarcoma
  • Humans
  • Matrix Metalloproteinase 2
  • Matrix Metalloproteinase 9
  • Matrix Metalloproteinases, Membrane-Associated
  • Metalloendopeptidases
  • Mice
  • Neprilysin
  • Peptide Fragments
  • Prodrugs
  • Reticulocytes
  • Transplantation, Heterologous
  • Tumor Cells, Cultured
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 1535-7163

Digital Object Identifier (DOI)

  • 10.1158/1535-7163.mct-05-0006

PubMed ID

  • 15897239
scroll to property group menus

Additional Document Info

start page

  • 751

end page

  • 760

volume

  • 4

issue

  • 5

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support